Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick): Long-term results of a large European multicentric phase III study

Cancer

Volumn 97, Issue 8, 2003, Pages 1941-1946

  Khayat, David ^a   Rixe, Olivier ^a   Martin, Ginette ^b   Soubrane, Claude ^a   Banzet, Martine ^a   Bazex, Jacques André ^c   Lauret, Philippe ^d   Vérola, Olivier ^e   Auclerc, Gérard ^a   Harper, Peter ^f   Banzet, Pierre ^e  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c CHU PURPAN   (France)

^d HÔPITAL CHARLES NICOLLE   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Immunotherapy; Malignant melanoma; Prognostic factors; Surgery

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DACARBAZINE; FOTEMUSTINE; INTERLEUKIN 2; METHISOPRINOL;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; EXCISION; FEMALE; FINGER; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAIL; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; TOE;

ADULT; BIOPSY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 0037446046     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11272     Document Type: Article

References (13)

1. Balch CM, Murad TM, Soong S-J, et al. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg. 1978;188:732-742.
2. Balch CM, Soong S-J, Milton GW, et al. A comparison of prognostic factors and surgical results in 1786 patients with localized (Stage I) melanoma treated in Alabama, USA and New South Wales, Australia. Ann Surg. 1982;196:677-684.
3. Balch CM, Murad TM, Soong S-J, et al. Tumor thickness as a guide to surgical management of clinical Stage I melanoma patients. Cancer. 1979;43:883-888.
4. Veronesi U, Cascinelli N. Narrow excision (1 cm margin) a safe procedure for thin cutaneous melanoma. Arch Surg. 1991;126:438-441.
5. Balch CM, Urist MM, Constantine P, et al. Efficacy of a 2 cm surgical margin for intermediate thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg. 1993;218:262-269.
6. Armstrong BK, Kricker A. Cutaneous melanoma. Cancer Surv. 1994;19:219-240.
7. Elwood JM. Recent developments in melanoma epidemiology. Melanoma Res. 1993;3:149-156.
8. Mackie RM, Hole D. Audit of public education campaign to encourage earlier detection of malignant melanoma. BMJ. 1992;304:1012-1015.
9. Mackie RM, Hunter JAA, Blessing K, et al. Changing tumor thickness in melanomas in Scotland 1979-1989. Melanoma Res. 1993;3(Suppl 1):60.
10. Burton RC, Armstrong BK. Recent incidence trends imply a non-metastasizing form of invasive melanoma. Melanoma Res. 1994;4:107-113.
11. Burton RC. Analysis of public education and the implications with regard to nonprogressive thin melanomas. Curr Opin Oncol. 1995;7:170-174.
12. Pompidou A, Soubrane C, Cour V, Telvi L, Meunier C, Jacquillat C. Immunological effects of isoprinosine as a pulse immunotherapy in melanoma and ARC patients. Cancer Detect Prev. 1987;(Suppl 1):457-462.
13. Cohn-Cedermark G, Rutqvist LE, Andersoson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer. 2000:89: 1495-1501.